A patient receiving intravitreal bevacizumab (Avastin) for diabetic retinopathy is referred for HBO for a diabetic foot wound. The primary consideration is:
-
A
Bevacizumab may be inactivated by high-pressure oxygen
-
B
Anti-VEGF therapy may theoretically counteract HBO-stimulated angiogenesis
-
C
Bevacizumab significantly increases retinal oxygen toxicity risk
-
D
The combination is absolutely contraindicated with no exceptions